Recursion Pharmaceuticals, Inc. (RXRX) stock experienced a significant surge in pre-market trading on Tuesday, soaring 13.82%. The rally came after tech giant Nvidia disclosed that it maintained its investment in the medical AI company during the fourth quarter of 2024.
Nvidia's sustained backing of Recursion Pharmaceuticals has bolstered investor confidence in the company's prospects. Traders view Nvidia's continued investment as a vote of confidence in Recursion Pharmaceuticals' potential, fueling the pre-market rally.
The positive sentiment surrounding Recursion Pharmaceuticals was further amplified by Berkshire Hathaway's recent investment activities, including taking a new position in Constellation Brands. This move by the investment giant has injected optimism into the broader market, contributing to the stock's upward momentum.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。